1. Home
  2. PSTV vs KNRX Comparison

PSTV vs KNRX Comparison

Compare PSTV & KNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PSTV
  • KNRX
  • Stock Information
  • Founded
  • PSTV 1996
  • KNRX 2009
  • Country
  • PSTV United States
  • KNRX Singapore
  • Employees
  • PSTV N/A
  • KNRX N/A
  • Industry
  • PSTV Medical/Dental Instruments
  • KNRX Computer Software: Programming Data Processing
  • Sector
  • PSTV Health Care
  • KNRX Technology
  • Exchange
  • PSTV Nasdaq
  • KNRX Nasdaq
  • Market Cap
  • PSTV 61.1M
  • KNRX 49.9M
  • IPO Year
  • PSTV N/A
  • KNRX 2025
  • Fundamental
  • Price
  • PSTV $0.61
  • KNRX $1.95
  • Analyst Decision
  • PSTV Strong Buy
  • KNRX
  • Analyst Count
  • PSTV 4
  • KNRX 0
  • Target Price
  • PSTV $7.25
  • KNRX N/A
  • AVG Volume (30 Days)
  • PSTV 5.7M
  • KNRX 33.7K
  • Earning Date
  • PSTV 10-30-2025
  • KNRX 06-12-2026
  • Dividend Yield
  • PSTV N/A
  • KNRX N/A
  • EPS Growth
  • PSTV N/A
  • KNRX N/A
  • EPS
  • PSTV N/A
  • KNRX N/A
  • Revenue
  • PSTV $5,258,000.00
  • KNRX $10,820,365.00
  • Revenue This Year
  • PSTV $9.91
  • KNRX N/A
  • Revenue Next Year
  • PSTV $1.06
  • KNRX N/A
  • P/E Ratio
  • PSTV N/A
  • KNRX N/A
  • Revenue Growth
  • PSTV N/A
  • KNRX 24.00
  • 52 Week Low
  • PSTV $0.16
  • KNRX $1.25
  • 52 Week High
  • PSTV $2.31
  • KNRX $4.00
  • Technical
  • Relative Strength Index (RSI)
  • PSTV 57.26
  • KNRX N/A
  • Support Level
  • PSTV $0.48
  • KNRX N/A
  • Resistance Level
  • PSTV $0.63
  • KNRX N/A
  • Average True Range (ATR)
  • PSTV 0.05
  • KNRX 0.00
  • MACD
  • PSTV 0.01
  • KNRX 0.00
  • Stochastic Oscillator
  • PSTV 86.96
  • KNRX 0.00

About PSTV PLUS THERAPEUTICS Inc.

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

About KNRX KNOREX LTD. Class A Ordinary Shares

Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. Its software offers marketers cost-effective solutions and productivity-enhancing capabilities to target audience across various advertising channels and devices through automated processes and algorithms, which is known as programmatic advertising. Its product, Knorex XPOSM, is a self-service enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications. The Company operates in one operating segment, which focuses on platform subscription fee, platform services, managed activations, and professional services.

Share on Social Networks: